As a clinical physician assistant student in internal medicine, what are the different classes of antiarrhythmic drugs used for atrial fibrillation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Antiarrhythmic Drug Classes for Atrial Fibrillation

Antiarrhythmic drugs for AF are organized into four Vaughan Williams classes, with selection driven primarily by safety considerations based on your patient's structural heart disease status, not by efficacy, since all drugs have similar modest effectiveness at maintaining sinus rhythm. 1

The Four Classes: A Practical Framework

Class I: Sodium Channel Blockers

These drugs block the fast-inward sodium channel on myocardium and are subdivided into three groups:

Class IA (Moderate sodium channel blockade + potassium channel blockade):

  • Quinidine, Disopyramide, Procainamide
  • These are largely historical agents now, associated with increased all-cause mortality (OR 2.39) 1
  • Rarely used as first-line therapy due to toxicity concerns 2

Class IC (Strong sodium channel blockade):

  • Flecainide and Propafenone - these are your go-to agents for patients without structural heart disease 1
  • Critical safety restriction: Only use in patients without ischemic heart disease or heart failure to avoid life-threatening ventricular arrhythmias 1
  • Important caveat: Must pre-administer a beta-blocker, verapamil, or diltiazem to prevent high ventricular rates if AF converts to atrial flutter with 1:1 conduction 1
  • Can be used as "pill-in-the-pocket" for acute conversion in selected patients 2

Class II: Beta-Blockers

  • Metoprolol, Atenolol, Propranolol, Esmolol, Carvedilol, Bisoprolol 3
  • Primary role is rate control, not rhythm control 4
  • First-line for rate control in most patients, especially those with ACS, thyrotoxicosis, or post-operative AF 3
  • Generally safe and do not require therapeutic drug monitoring 5

Class III: Potassium Channel Blockers

This is where most of your rhythm control decisions happen:

Amiodarone:

  • Most effective antiarrhythmic but second-line due to significant extracardiac toxicity (thyroid, pulmonary, hepatic, ocular) 1
  • Safe in heart failure and structural heart disease - use when other agents are contraindicated 1
  • Can cause torsades de pointes; monitor QT interval 1
  • Requires loading (300 mg IV over 1 hour, then 10-50 mg/h for 24h; oral 100-200 mg daily) 3

Dronedarone:

  • Maintains sinus rhythm and reduces cardiovascular hospitalizations 1
  • Contraindicated in recently decompensated heart failure and permanent AF (increases mortality in these populations) 1
  • Safer extracardiac profile than amiodarone 1

Sotalol:

  • Beta-blocker properties plus Class III effects 6
  • Requires careful evaluation of proarrhythmic risk (torsades de pointes) 1
  • Should not be used in patients with heart failure with reduced ejection fraction 7
  • Dose adjusted for renal function 6

Dofetilide:

  • Highly effective but must be initiated inpatient with continuous monitoring 6
  • Dose adjusted based on renal function with close QT monitoring 6
  • Guideline-concordant use rate is 93% (highest among all AADs) 8

Class IV: Calcium Channel Blockers

  • Diltiazem and Verapamil (non-dihydropyridines only) 3
  • Used for rate control, not rhythm control 4
  • First-line for rate control in COPD patients (where beta-blockers are contraindicated) 3
  • Monitored by hemodynamic effects rather than drug levels 5

The Safety-First Algorithm for Drug Selection

The 2016 ESC guidelines explicitly state: "Safety rather than efficacy considerations should primarily guide the choice of antiarrhythmic drug" 1

Step 1: Assess for Structural Heart Disease

No Structural Heart Disease (including no CAD, no LV hypertrophy, no heart failure):

  • First choice: Flecainide or Propafenone 1
  • Alternative: Dronedarone, Sotalol (with proarrhythmic risk assessment) 1

Hypertension with LV Hypertrophy:

  • Avoid Class IA/III agents (increased torsades risk) 9
  • Consider: Dronedarone, Amiodarone 1

Coronary Artery Disease or Heart Failure:

  • Absolutely avoid Class IC agents (increased risk of sustained VF/VT) 1, 9
  • First choice: Amiodarone (safest in structural heart disease) 1
  • Alternative: Dofetilide, Sotalol (if no HFrEF) 3

Heart Failure with Reduced Ejection Fraction:

  • Only safe options: Amiodarone or Dofetilide 1
  • Dronedarone is contraindicated (increases mortality) 1

Step 2: Consider Clinical Context

Acute Cardioversion:

  • IV: Ibutilide, Flecainide, Propafenone (Class I recommendation) 3
  • Amiodarone reasonable but slower acting 2

Maintenance Therapy:

  • Most patients should NOT be placed on rhythm maintenance therapy (risks outweigh benefits) 4
  • Only use in selected patients whose quality of life is significantly compromised by AF 4

Rate Control Only:

  • Beta-blockers, diltiazem, verapamil (Class I) 4
  • Digoxin is second-line (only effective at rest, not during exercise) 4

Critical Safety Pitfalls to Avoid

  1. Never use Class IC drugs in patients with any structural heart disease - this is the most common and dangerous error 1, 9

  2. Never use dronedarone in decompensated heart failure or permanent AF - associated with increased mortality 1

  3. Never use IV adenosine, digoxin, diltiazem, verapamil, or amiodarone in Wolff-Parkinson-White with pre-excited AF - these accelerate ventricular rate and can cause VF 3

  4. Always pre-treat with AV nodal blocking agents before starting flecainide or propafenone to prevent 1:1 flutter conduction 1

  5. Sotalol and dofetilide require QT monitoring and renal dose adjustment - high torsades risk without proper monitoring 6

  6. Digoxin and sotalol are harmful for acute pharmacological cardioversion 2

Real-World Prescription Patterns

Despite guidelines, amiodarone remains the most commonly prescribed AAD (38% of patients), followed by sotalol (23%) and dofetilide (19%), with flecainide and propafenone significantly underutilized 8. This represents overuse of amiodarone in patients without structural heart disease and inappropriate sotalol use in HFrEF patients 7, 8. Overall guideline-concordant prescribing is 84%, but varies significantly by drug: dofetilide 93%, dronedarone 80%, flecainide 68%, sotalol 66%, propafenone 48% 8.

Key Teaching Points

  • Efficacy is similar across all AADs - they approximately double sinus rhythm maintenance compared to no therapy, but none dramatically outperform others 1
  • Antiarrhythmic drugs do not reduce mortality or cardiovascular complications 1
  • Rate control with anticoagulation is the recommended strategy for most patients - rhythm control is appropriate based on symptoms, exercise tolerance, and patient preference 4
  • All patients with AF need stroke risk assessment and anticoagulation regardless of rhythm control strategy 4

References

5
Research

Therapeutic drug monitoring: antiarrhythmic drugs.

British journal of clinical pharmacology, 1998

7
Research

Chapter 5: Guideline Recommendations: Which AAD and for Whom?

The American journal of cardiology, 2023

9
Research

Drug choices in the treatment of atrial fibrillation.

The American journal of cardiology, 2000

Related Questions

What is the appropriate pharmacologic agent for rhythm control in an adult patient with atrial fibrillation who has no structural heart disease, coronary artery disease, left ventricular dysfunction, or prolonged QT interval?
How long should you wait before increasing the diltiazem (Dilt) drip?
What is the appropriate amiodarone regimen for converting and controlling atrial fibrillation, including dosing, monitoring, and alternative options?
In a hemodynamically stable patient with rapid‑ventricular‑response atrial fibrillation and no contraindications, what is the recommended repeat dosing regimen of intravenous amiodarone?
In an elderly patient who underwent cardioversion and had amiodarone (Multaq) discontinued after a breakthrough atrial fibrillation within five days, can sinus rhythm be maintained with beta‑blocker therapy alone?
When is CA 19‑9 indicated, what is the normal cutoff, and how should elevated results be interpreted and managed?
What are the target TSH and free T4 levels for a pregnant patient being treated for hyperthyroidism?
Can ultrasound diagnose a torn rotator cuff?
Is a paraganglioma a contraindication for electroconvulsive therapy (ECT)?
What is polypharmacy?
What is the appropriate evaluation and management of persistent halitosis in a toddler?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.